Phase 3 now enrolling
As a result of extremely promising results of Phase 2 trials, Cymabay Therapeutics is now enrolling patients in a Phase 3 study for Seladelpar. This is a 52 week triple blind study. Read more about this study here.
As a result of extremely promising results of Phase 2 trials, Cymabay Therapeutics is now enrolling patients in a Phase 3 study for Seladelpar. This is a 52 week triple blind study. Read more about this study here.